219 related articles for article (PubMed ID: 17413766)
1. Heparin-like anticoagulant associated with multiple myeloma and neutralized with protamine sulfate.
Torjemane L; Guermazi S; Ladeb S; Ben Romdhane N; Lakhal A; Abdelkefi A; Ben Othman T; Ben Abdelhadhim A
Blood Coagul Fibrinolysis; 2007 Apr; 18(3):279-81. PubMed ID: 17413766
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of enoxaparine-induced bleeding by protamine sulfate.
Van Ryn-McKenna J; Cai L; Ofosu FA; Hirsh J; Buchanan MR
Thromb Haemost; 1990 Apr; 63(2):271-4. PubMed ID: 2163553
[TBL] [Abstract][Full Text] [Related]
3. Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder.
Palmer RN; Rick ME; Rick PD; Zeller JA; Gralnick HR
N Engl J Med; 1984 Jun; 310(26):1696-9. PubMed ID: 6233489
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of SR 90107A/Org 31540-induced bleeding by protamine sulfate in rats and mice.
Bernat A; Hoffmann P; Herbert JM
Thromb Haemost; 1996 Nov; 76(5):715-9. PubMed ID: 8950779
[TBL] [Abstract][Full Text] [Related]
5. Heparin-like anticoagulant associated with plasma cell myeloma.
Chapman GS; George CB; Danley DL
Am J Clin Pathol; 1985 Jun; 83(6):764-6. PubMed ID: 3923825
[TBL] [Abstract][Full Text] [Related]
6. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?
Teoh KH; Young E; Blackall MH; Roberts RS; Hirsh J
J Thorac Cardiovasc Surg; 2004 Aug; 128(2):211-9. PubMed ID: 15282457
[TBL] [Abstract][Full Text] [Related]
7. Reversal of life-threatening bleeding with protamine sulfate in a patient with plasma cell leukemia.
VanDommelen K; Omer Z; Hambley BC; Stefaniuk CM
Blood Coagul Fibrinolysis; 2022 Oct; 33(7):425-428. PubMed ID: 35946464
[TBL] [Abstract][Full Text] [Related]
8. Acquired dysfibrinogenemia secondary to multiple myeloma.
Kotlín R; Sobotková A; Riedel T; Salaj P; Suttnar J; Reicheltová Z; Májek P; Khaznadar T; Dyr JE
Acta Haematol; 2008; 120(2):75-81. PubMed ID: 18841003
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulant activity in cell-free peritoneal fluid of an experimental pancreatic ascites tumor.
Ts'ao C; Galluzzo TS; Hart SJ; Ng AS; Sorenson PG; Subbarao V
Thromb Haemost; 1985 Dec; 54(4):768-72. PubMed ID: 3003955
[TBL] [Abstract][Full Text] [Related]
10. Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder.
Khoory MS; Nesheim ME; Bowie EJ; Mann KG
J Clin Invest; 1980 Mar; 65(3):666-74. PubMed ID: 6444419
[TBL] [Abstract][Full Text] [Related]
11. Removal of heparin and protamine from plasma.
Thompson AR; Counts RB
J Lab Clin Med; 1976 Dec; 88(6):922-9. PubMed ID: 993645
[TBL] [Abstract][Full Text] [Related]
12. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of recombinant platelet factor 4 and protamine sulfate for heparin neutralization: clotting and clearance studies in rat.
Korutla LN; Stewart GJ; Lasz EC; Maione TE; Niewiarowski S
Thromb Haemost; 1994 May; 71(5):609-14. PubMed ID: 8091389
[TBL] [Abstract][Full Text] [Related]
14. [A heparin-like anticoagulant in a patient with Wegener's granulomatosis].
Chrobák L; Rozsíval V; Herout V
Bratisl Lek Listy; 1990 May; 91(5):396-8. PubMed ID: 2383776
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant effects of protamine sulfate in a canine model.
Kresowik TF; Wakefield TW; Fessler RD; Stanley JC
J Surg Res; 1988 Jul; 45(1):8-14. PubMed ID: 3392995
[TBL] [Abstract][Full Text] [Related]
16. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
[TBL] [Abstract][Full Text] [Related]
17. Tumor immunoglobulin with antibody activity against blood coagulation factors.
Antonucci M; Berard M; Beaumont JL
J Med; 1986; 17(3-4):149-65. PubMed ID: 3473163
[TBL] [Abstract][Full Text] [Related]
18. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
[TBL] [Abstract][Full Text] [Related]
19. Acquired heparin-like anticoagulation process in a patient with multiple myeloma: a case report and literature review.
Shen H; Wu C; Chen L; Zhang R
Transl Cancer Res; 2020 Nov; 9(11):7366-7371. PubMed ID: 35117336
[TBL] [Abstract][Full Text] [Related]
20. Intentional overdose with tinzaparin: management dilemmas.
Balla I; Karafotias I; Christopoulos C
J Emerg Med; 2014 Feb; 46(2):197-201. PubMed ID: 24084058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
